地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:15172431432
邮箱:sales@amyjet.com

艾美捷科技代理Prolytix品牌脂质组学和氧化脂质生物标志物相关产品。
Prolytix是一家专注于脂质组学和氧化脂质生物标志物研究的公司,致力于为生物医学研究和临床诊断提供高质量的脂质分析服务和产品。总部:位于美国佛蒙特州伯灵顿市。
Prolytix公司核心业务包括:
(1)脂质组学分析,提供全面的脂质组学分析服务,包括氧化脂质、磷脂、鞘脂等的定量和定性分析;
(2)生物标志物开发,开发和验证与疾病相关的脂质生物标志物,用于早期诊断和疾病监测;
(3)定制化解决方案:根据客户需求,提供定制化的脂质分析方案和研究服务。
Prolytix公司的产品包括氧化脂质标准品、脂质分析试剂盒、脂质组学分析软件等。Prolytix公司产品广泛应用于:
(1)生物医学研究:广泛应用于心血管疾病、癌症、神经退行性疾病等研究领域。
(2)临床诊断:支持脂质生物标志物的开发和临床应用,助力疾病早期诊断和个性化治疗。
(3)药物开发:用于药物靶点发现、药效评价和安全性评估。
<<<<< " data-original="http://hooke.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Prolytix品牌"> 艾美捷科技代理Prolytix品牌
艾美捷科技代理Diaclone品牌检测试剂。
Diaclone是一家集酶联免疫试剂盒、流式抗体为一体的公司,在炎症、肿瘤、免疫学领域深耕多年;ELISA 试剂盒可对细胞因子、趋化因子、 生长因子进行有效检测。Diaclone的产品线主要包括:细胞因子和细胞黏附分子的抗体:这些抗体被广泛应用于酶联免疫检测试剂盒中,用于检测和量化细胞因子和细胞黏附分子的表达水平。酶联免疫试剂盒(ELISA):Diaclone提供多种规格和型号的ELISA试剂盒,用于检测各种生物样本中的特定抗原或抗体。这些试剂盒具有灵敏度高、特异性强、操作简便等特点。酶联免疫斑点检测试剂盒(ELISpot):ELISpot技术是一种用于检测细胞分泌特定蛋白质(如细胞因子)的灵敏方法。Diaclone的ELISpot试剂盒可用于研究细胞免疫应答,如T细胞活性等。
" data-original="http://hooke.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Diaclone品牌检测试剂"> 艾美捷科技代理Diaclone品牌检测试剂

艾美捷科技代理Gene Tools品牌
Gene Tools是一家生产和销售Morpholino Anti-sense oligos(反义寡核苷酸)的公司,其产品专门用于基因调控的科学研究和药物开发。Gene Tools公司由多位资深科学家组成,为全球客户提供免费的技术咨询和Morpholino 序列设计服务。 Morpholino作为基因调控研究的最佳工具,已被广泛用于:阻断靶mRNA 翻译 (下调基因);诱导RNA选择性剪接 (下调或上调基因);阻断 miRNA;阻断病毒 RNA;阻断 non-coding RNA。
▍Morpholino介绍
Morpholino属于第三代反义寡核苷酸,主要通过阻断蛋白质翻译过程而达到抑制目标基因功能的作用,目前已经广泛用于发育生物学和细胞学实验中,并取得了非常好的实验效果。
Morpholino以吗啉环类似物为基本骨架,这种独特的结构特性使得Morpholino 具有以下几个特点:
● 与其他类型的反义寡核苷酸相比,Morpholino 能更好地抵抗核酸酶的作用;
● Morpholino 与靶序列结合后通过空间位阻效应发挥作用, 不激活RNaseH,不引起目标基因mRNA 的降解 ;
● 针对翻译起始位点区设计的Morpholino 用于抑制蛋白质的翻译,针对 pre-mRNA 剪切位点区设计的Morpholino 可影响mRNA 剪切,得到不 同的转录本,可以方便地用于目标基因结构域的突变研究;
● 与靶序列结合能力强,可以渗入mRNA 的二级结构, 并且特异性好。
配合Morpholino 的使用,Gene Tools公司开发了相应的递送系统,可以安全、高效地将Morpholino 输送至胞内,因此,Morpholino 也可以用于遗传学研究和新药靶标的发现以及验证。此外,Morpholino 可以标上荧光基团、亲和标签以及活性反应基团,以供不同的研究需要。

▍Gene Tools公司产品介绍
● Custom Morpholino:可以根据目标基因序列定制设计并合成Morpholino,用于体外细胞实验或某些直接显微注射的模型(如斑马鱼、非洲爪蟾胚胎)。
● Vivo-Morpholino:适用于活体动物模型(小鼠,大鼠,狗,灵长类等),细胞培养,器官培养等。通过特殊的末端修饰,提高了其穿透细胞膜进入组织细胞的能力,使得在成年动物(主要是小鼠、大鼠)中进行系统性基因功能研究成为可能。
● Prepared Control Oligos:根据特定需求合成细胞穿透肽偶联的 Morpholino。适用于活体动物模型(小鼠,大鼠,狗,灵长类等),细胞培养,器官培养等。
| 产品名称 | Short Description | Oligo sequence | SKU |
| Standard Control Oligo | Negative control oligo | CCTCTTACCTCAGTTACAATTTATA | PCO-StandardControl-100 |
| Vivo-Morpholino Standard Control Oligo | Negative Vivo-Morpholino control oligo | CCTCTTACCTCAGTTACAATTTATA | PCO-VivoStandardControl-100 |
| Random Control Oligo 25-N | 25-base random sequence mixture | NNNNNNNNNNNNNNNNNNNNNNNNN | PCO-RandomControl-25N-100 |
| Zebrafish p53 oligo | Danio rerio apoptosis suppression oligo | GCGCCATTGCTTTGCAAGAATTG | PCO-ZebrafishP53-100 |
| Zebrafish Chordin Positive Control Oligo | Danio rerio Chordin positive control oligo | ATCCACAGCAGCCCCTCCATCATCC | PCO-ZebrafishChordin-100-F |
| Clawed Frog Beta Catenin Positive Control Oligo | Xenopus laevis Beta Catenin antisense oligo | TTTCAACCGTTTCCAAAGAACCAGG | PCO-BetaCatenin-100-F |
| Green Fluorescent Protein Positive Control | Translation blocker for GFP target | ACAGCTCCTCGCCCTTGCTCACCAT | PCO-GFPControl-100 |
| Vivo-Morpholino GFP Positive Control | Translation blocker for GFP target (Vivo-Morpholino) | ACAGCTCCTCGCCCTTGCTCACCAT | PCO-VivoGFPControl-100 |
| Fluoresceinated Vivo-Morpholino Std Control | Negative Vivo-Morpholino control oligo with 5'Fluorescein | CCTCTTACCTCAGTTACAATTTATA | PCO-FluorVivoStandardControl-100-F |
● Endo-Porter:为了解决Morpholino在体外培养细胞中摄取效率低的问题,Gene Tools 开发了 Endo-Porter 这种特殊的转染试剂。它通过温和的内吞体逃逸机制帮助Morpholino进入细胞质。
<艾美捷科技代理GenTegra品牌全系列产品
GenTegra 凭借专业的研发团队和深厚的技术积累,GenTegra 在生物样本保护领域处于领先地位,其产品广泛应用于科研、医疗、法医等多个领域。GenTegra 开发的产品包括适用于多种应用场景的样本采集装置,例如:用于基因组学和转录组学分析的 RNASeq 样本采集;对犯罪现场法医样本进行 DNA 分析的样本采集;来自患者自采样设备的全血样本采集。GenTegra公司的产品包括GenTegra RNA、GenTegra DNA。

▍GenTegra公司的产品
● GenTegra RNA 相关产品
①GenTegra RNA Advantage:使用 RIN 值作为 RNA 质量的衡量标准,能为组织中的 RNA 提供更好保护。相比 RNAlater 等产品,它始终产生 RIN 分数更好(≥1)的 RNA,且使用时 RIN 值等于或高于所需的 RIN 值≥7,确保出色的 RNAseq 结果,可替代 RNAlater 而无需更改当前方案。
②GenTegra RNA:是在实验室工作或运输 RNA 时为 RNA 提供的最佳保护产品。作为水溶性活性化学保护剂,添加到 RNA 中会形成保护基质,在干燥状态和液态下都能保存和保护 RNA。在 -80°C 至 +72°C 的极端温度下保护近乎完美,是唯一一种在干燥前立即提供 RNase 活性保护的干式储存产品,允许使用所有标准缓冲系统。在室温下储存保质期超过 3 年,有多种包装形式,如 100/0.5ml 螺旋盖管、96 孔微孔板或 96 管架格式、足够数量的散装基质,还提供三管评估套件。
③GenTegra RNAssure™:为 RNA 纯化和 RNAseq 的人员提供新水平的保护。其专有的活性化学保护™ ACP 配方可在洗脱纯化柱时立即保护 RNA,提供更彻底的保护,能保护样品完整性,可无缝融入每个标准 RNA 纯化试剂盒中,在室温(RT)下保护 RNA 至少 3 天,在 4°C 下保护 RNA 2 周,还可以保护 RNA 在 37°C 的较高温度下进行 DNase 处理期间免受损伤,能灭活纯化过程或环境污染遗留的所有残留 RNase 活性,保护 DNase 免受氧化损伤等。
● GenTegra - DNA 相关产品
①GenTegra - DNA:在运输和储存过程中的极端温度(-80°C 至 +72°C)下都能对 DNA 进行保护,基于加速研究在环境温度下保护 DNA 超过 20 年,无需特殊环境控制即可保护 DNA,经过多次干燥和补水循环。
②GenTegraDNA dry BULK:是法医实验室的首选产品,干散货是自动化系统的理想选择,支持直接用于 STR、qPCR 等,在需要时支持 DNA 样品浓缩,干燥的 DNA 样品可以在环境温度下安全运输,在室温下储存的保质期超过 3 年,提供三管评估套件。
● GenSolve DNA 提取和纯化试剂盒
①GenSolve Complete提取和纯化试剂盒:经过优化的提取和纯化方法,可提供最高质量的干血斑结果,能从任何可用的DNA采集卡中提取和纯化DNA,基于柱的纯化过程可有效将DNA与细胞碎片和外来化学成分分离。
②GenSolve DNA 提取试剂盒:可灵活地利用GenTegra 行业领先的DNA 提取技术来检测干血斑,并提供任何可用的DNA纯化试剂盒。来自任何采集卡的干血斑的 DNA 数量无与伦比,与GenTegra GenSaver卡或GenPlates结合使用时,产量为 95%,可与所需的任何DNA纯化方法配对。
▍GenTegra产品列表
| 产品名称 | 产品描述 |
| GenTegra RNAdvantage™ | 为新鲜组织样本中的 RNA 提供更优保护。 |
| GenTegra RNAssure™ | 对直接来源于 RNA 纯化试剂盒的 RNA 提供即时且完全的保护。 |
| GentegraRNA | 为运输用于 RNA 测序 (RNAseq) 的 RNA 提供即时且完全的保护。 |
| GenTegraDNA | 为生命科学和法医实验室应用提供卓越的 DNA 保护 |
| GenSolve COMPLETE 提取与纯化试剂盒 | 能够从干血斑中提取出最高质量、长度 >35 kb且高产量的 DNA。 |
| GenSolve 经典提取试剂盒 | 干血斑(DBS)DNA 提取技术可与任何 DNA 纯化试剂盒结合使用。 |
| GenTegra 快速干燥仪 | 可用于将生物样品施加到 GenTegra-RNA、GenTegra-DNA 或 GenPlate 之后进行干燥处理。 |
| enSaver DNA 卡 | 有 1 点、2 点和 4 点格式可供选择。变色格式适用于收集唾液等透明样本。 |
| GenSaver 2.0 法医 DNA 卡 | 该卡有 1 点、2 点和 4 点格式可供选择,其中变色格式适用于收集唾液等透明样本。 |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://hooke.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理DNA Polymerase Technology品牌全系列产品
DNA Polymerase Technology的核心领域是PCR(聚合酶链式反应),致力于通过先进的转基因酶和其他PCR产品,克服多个领域中的常见障碍,包括临床诊断、法医分析、食品安全、环境中病原体检测以及一般分子生物学研究。Klentaq公司发明的新型酶进一步提升了PCR性能,具有以下特点:扩增更长的目标片段,具有更高的保真度,反应速度更快,并且能够耐受血液或土壤等抑制性污染物。该公司产品线包括:Klentaq产品、OmniTaq产品、ZipTaq产品、 Long &Accurate 的产品、热启动产品、热启动LA产品、Lyoph-Ready产品、PCR增强剂和缓冲液、PCR试剂盒以及组合产品。此外,公司开发的其他技术还包括:PCR增强剂组合以及热启动缓冲液。

▍DNA Polymerase Technology公司产品线
● Klentaq 产品:5-核酸外切酶缺陷型 Taq 聚合酶可提供更高的保真度和热稳定性,特别是作为 LA(长准确)酶混合物的一部分。Klentag1是 Jag DNA 聚合酶的 Klenow 片段类似物。它是已知最耐热的 Tag 形式,完全不具备核酸外切酶或内切酶活性,并且其晶体结构已被解析清楚。该酶的 LA版本是 Klentag1 和校对酶的混合物。
| 品名 | 货号 | 规格 |
| Klentag1 | 100 | 100 ul (2,000 X25 ul rxns up to1kb) |
| Omni Klentag | 340 | 125 ul (500 x 25ul rxns) |
| Omni Klentag2 | 342 | 125 ul (500 x 25ul rxns) |
| Omni Klentag C | 280 | 100 ul (2,000 X25 ul rxns) |
| Omni Klentag AC | 240 | 100 ul (2,000 X25 ul rxns) |
| Omni Klentag-S | 105 | 100 ul (2,000 X25 ul rxns up to1 kb) |
● OmniTag 产品:Klentaq的抗抑制DNA聚合酶经过特殊筛选,对多种常见的高效PCR抑制剂(例如:全血、血清、血浆、尿液、腐殖酸、胆盐、植物组织提取物、各类食品相关抑制剂、GITC(异硫氰酸胍)、乙醇等)具有极强的耐受性。因此,这些酶能在大多数市售Taq产品完全失效的抑制剂浓度下,依然进行有效的PCR扩增。Taq突变体的这一独特优势使得对多种临床样本、环境样本和法医样本进行免提取直接PCR成为可能,跳过了耗时的DNA提取步骤。
<| 品名 | 货号 | 规格 |
| OmniTag | 300 | 125 ul(500 X25 ul rxns) |
| OmniTaq 2 | 302 | 125 ul(500 X25 ul rxns) |
| OmniTag 2T | 302T | 250 rxns |
| OmniTag 3 | 303 | 125 ul(500 X25 ul rxns) |
● ZipTaq产品
<| 品名 | 货号 | 规格 |
| ZipTaq | 304 | 125 ul (500 X 25 ul rxns) |
● Long &Accurate 产品:使用 DNA 聚合酶和校对酶的专利组合,具有更高的保真度,是扩增长片段DNA目标序列的理想选择,此外,它们通常具备更强的稳健性,因此扩增短片段目标序列时同样适用。
| 品名 | 货号 | 规格 |
| Klentag LA | 110 | 100 ul (2,000 X25 ul rxns up to1 kb) |
| OmniTag LA | 310 | 125 ul(500 X25 ul rxns) |
| OmniTag 2LA | 312 | 125 ul (500 X25 ul rxns) |
| OmniTag 3LA | 313 | 125 ul (500 X25 ul rxns) |
| ZipTag LA | 314 | 125 ul(500 X25 ul rxns) |
| Omni KlentagLA | 350 | 125 ul(500 X25 ul rxns) |
| Omni Klentag2 LA | 344 | 125 ul (500 X25 ul rxns) |
| CesiumKlentag C LA | 290 | 100 ul(2,000 X25 ul rxns) |
| CesiumKlentag ACLA | 250 | 100 ul (2,000 X25 ul rxns) |
| CesiumTad | 210 | 100 ul(2,000 X25 ul rxns) |
| Klentaq-S LA | 115 | 100 ul(2,000 X25 ul rxns) |
● Klentaq的热启动技术包含:
①铯酶:它们是Taq或 Klentaq1 DNA聚合酶的双重冷敏感突变体,由于在低温下活性受到抑制,它们能为PCR提供自动热启动
②适配体抑制技术:适用于所有酶,在低于循环温度时,该适配体形成发夹结构并结合到聚合酶的活性位点,从而使酶失活并防止错误扩增
③LA产品:具有更高的保真度以及更强的稳健性
| 品名 | 货号 | 规格 |
| Hot Start Klentaq1 | HS100 | 100 ul (2,000 X 25 ul rxns up to 1kb) |
| Hot Start OmniTaq | HS300 | 125 ul (500 x 25 ul rxns) |
| Hot Start OmniTaq 2 | HS302 | 125 ul (500 X 25 ul rxns) |
| Hot Start OmniTaq 3 | HS303 | 125 ul (500 X 25 ul rxns) |
| Hot Start ZipTaq | HS304 | 125 ul (500 X 25 ul rxns) |
| Hot Start Omni Klentaq | HS340 | 125 ul (500 X 25 ul rxns) |
| Hot Start Omni Klentaq 2 | HS342 | 125 ul (500 X 25 ul rxns) |
| Hot Start Cesium Klentaq C | HS280 | 100ul (2000 x 25ul rxns) |
| Hot Start Cesium Klentaq AC | HS240 | 100ul (2000 x 25ul rxns) |
| CesiumTaq | 200 | 100 ul (2,000 X 25 ul rxns) |
| Hot Start CesiumTaq | HS200 | 100 ul (2,000 X 25 ul rxns) |
| Hot Start Klentaq-S | HS105 | 100 ul (2,000 X 25 ul rxns up to 1kb) |
| RockStart Buffer System | Rock100 | 100 rxns |
| Hot Start Klentaq LA | HS110 | 100 ul(2,000X 25 ul rxnsup to 1kb) |
| Hot Start OmniTaq LA | HS310 | 125 ul(500 x25 ul rxns) |
| Hot Start OmniTag 2 LA | HS312 | 125 ul (500 X25 ul rxns) |
| Hot Start OmniTag 3 LA | HS313 | 125 ul(500 X25 ul rxns) |
| Hot Start ZipTaq LA | HS314 | 125 ul(500 X25 ul rxns) |
| Hot Start Omni KlentagLA | HS350 | 125 ul(500 X25 ul rxns) |
| Hot Start Omni Klentag2 LA | HS344 | 125 ul(500 X25 ul rxns) |
| Hot Start CesiumKlentag C LA | HS290 | 100ul(2000 x25ul rxns) |
| Hot Start Cesium Klentag AC LA | HS250 | 100ul(2000 x25ul rxns) |
| Hot Start CesiumTag LA | HS210 | 100 ul (2,000X 25 ul rxns) |
● Lyoph-Ready 产品
<| 品名 | 货号 | 规格 |
| Klentag LA | 110 | 100 ul (2,000 X25 ul rxns up to1 kb) |
| OmniTag LA | 310 | 125 ul(500 X25 ul rxns) |
| OmniTag 2LA | 312 | 125 ul (500 X25 ul rxns) |
| OmniTag 3LA | 313 | 125 ul (500 X25 ul rxns) |
| ZipTag LA | 314 | 125 ul(500 X25 ul rxns) |
| Omni KlentagLA | 350 | 125 ul(500 X25 ul rxns) |
| Omni Klentag2 LA | 344 | 125 ul (500 X25 ul rxns) |
| CesiumKlentag C LA | 290 | 100 ul(2,000 X25 ul rxns) |
| CesiumKlentag ACLA | 250 | 100 ul (2,000 X25 ul rxns) |
| CesiumTad | 210 | 100 ul(2,000 X25 ul rxns) |
| Klentaq-S LA | 115 | 100 ul(2,000 X25 ul rxns) |
● PCR相关产品
①PCR增强剂和缓冲液产品:PEC 产品是非甜菜碱基 PCR 增强剂,专门设计用于抑制性模板。强烈建议将它们与我们的抑制抗性 Taq 和Klentag 突变体一起使用。它们还与大多数市售 DNA 聚合酶兼容。
②PCR 试剂盒产品:试剂盒包括 DNA 聚合酶、缓冲液和 dNTP,有标准套件和长而精确(LA) 套件。
③组合产品:测试多种酶和 PCR 增强剂混合物以优化 PCR 的一种经济高效的方法。
| 品名 | 货号 | 规格 |
| PCR Enhancer Cocktail 1 | E600 | 6.25 ml(for 500rxns of 25ul each) |
| PCR Enhancer Cocktail 2 | E620 | 6.25 ml(for 500rxns of 25ul each) |
| PCR Enhancer Cocktail 1 GC | E610 | 6.25 ml(for 500rxns of 25ul each) |
| PCR Enhancer Cocktail 2 GC | E630 | 6.25 ml(for 500rxns of 25ul each) |
| PCR Enhancer Cocktail P | E650 | 6.25 ml(for 500rxns of 25ul each) |
| 5M Betaine | EBET | 5 x 1.25ml |
| RockStartBuffer System | Rock100 | 100 rxns |
| 10x Klentag1Reaction BufferpH 9.2 | RB20 | 3 ml |
| 10x Klentag1Reaction BufferpH 7.9 | RB21 | 3 ml |
| 10x KlentagMutant ReactionBuffer | RB10 | 3 ml |
| 10x Tag MutantReaction Buffer | RB30 | 3 ml |
| 10x RT-LAMPReaction Buffer | RB40 | 3 ml |
| 10x ZipTaqReaction Buffer | RB60 | 3 ml |
| 10x Klentag-SReaction Buffer | RB70 | 3 ml |
| Storage/DilutionBuffer | SB | 3ml |
| 5x Klentag1 PCR Kit | 120 | 500 x 25 ul rxns |
| 5x Klentag LA PCR Kit | 130 | 500 x 25 ul rxns |
| 5x Hot Start Klentag1 PCR Kit | HS120 | 500 x25 ul rxns |
| 5x OmniTag PCR Kit | 320 | 500 x 25 ul rxns |
| 5x omniTag LA PCR Kit | 330 | 500 x25 ul rxns |
| 5x Hot Start omniTag PCR Kit | HS320 | 500 x 25 ul rxns |
| 5x OmniTag 2 PCR Kit | 322 | 500 X 25 ul rxns |
| 5x OmniTag 2 LA PCR Kit | 332 | 500 X 25 ul rxns |
| 5x Hot Start omniTag 2 PCR Kit | HS322 | 500 x25 ul rxns |
| 5x OmniTag 3 PCR Kit | 323 | 500 X 25 ul rxns |
| 5x OmniTag 3 LA PCR Kit | 333 | 500 X 25 ul rxns |
| 5x Hot Start OmniTag 3 PCR Kit | HS323 | 500 x25 ul rxns |
| 5x ZipTaq PCR Kit | 324 | 500 x25 ul rxns |
| 5x Hot Start ZipTag Kit | HS324 | 500 x 25 ul rxns |
| 5x Omni Klentag PCR Kit | 360 | 500 X 25 ul rxns |
| 5x Omni Klentag LA PCR Kit | 370 | 500 X 25 ul rxns |
| 5x Hot Start Omni Klentag PCR Kit | HS360 | 500 x25 ul rxns |
| 5x omni Klentag 2 PCR Kit | 362 | 500 X 25 ul rxns |
| 5x Omni Klentag 2 LA PCR Kit | 372 | 500 X 25 ul rxns |
| 5x Hot Start Omni Klentag 2 PCR Kit | HS362 | 500 x25 ul rxns |
| 5x Cesium Klentag C PCR Kit | 285 | 2,000 x 25 ul rxns |
| 5x Cesium Klentag C LA PCR Kit | 295 | 2,000 x 25 ul rxns |
| 5x Hot Start Cesium Klentag CPCR Kit | HS285 | 2,000 x 25 ul rxns |
| 5x Cesium Klentag AC PCR Kit | 260 | 2.000 x 25 urxns |
| 5x Cesium Klentag AC LA PCR Kit | 270 | 2.000 x 25 urxns |
| 5x Hot Start Cesium Klentag AC PCR Kit | HS260 | 2,000 x25 urxns |
| 5x CesiumTag PCR Kit | 220 | 2,000 x 25 urxns |
| 5x CesiumTag LA PCR Kit | 230 | 2,000 x25 ulrxns |
| 5x Hot Start CesiumTag PCR Kit | HS220 | 2.000 x25 urxns |
| 5x Klentag-S PCR Kit | 125 | 500 x25ul rxns |
| Enzyme combo | 500 | variable |
| Enzyme Combo LA | 510 | variable |
| Hot Start Enzyme Combo | HS500 | variable |
| Hot Start Enzyme Combo LA | HS510 | variable |
| PCR Enhancer Cocktail Combo | E640 | 1.25 ml eachenhancer |

艾美捷科技代理MiTeGen品牌结构生物学相关工具产品。
MiTeGen是一家专注于为结构生物学研究提供高质量工具和设备的公司,其产品广泛应用于结构生物学、药物开发、蛋白质工程、材料科学等领域。MiTeGen公司以其创新的样品制备技术和高通量结晶工具闻名。
MiTeGen的主要产品包括:
(1)MicroMounts
用于蛋白质结晶的微型样品固定工具,适用于X射线衍射实验。
特点:高精度、低背景噪音,兼容多种实验条件。
(2)MiTeGen Loops
用于蛋白质结晶实验的样品环,提供多种尺寸和材质。
特点:高机械强度、低X射线散射,适合高分辨率数据采集。
(3)Crystallization Plates
高通量结晶板,支持自动化实验。
特点:设计紧凑,兼容机器人系统,适合大规模筛选。
(4)Cryo-Tools
用于低温样品处理的工具,如低温夹和低温盒。
特点:高效冷却,防止冰晶形成,确保样品完整性。
(5)CrystalCap
用于保护结晶样品的帽盖,防止样品干燥和污染。
特点:易于使用,兼容多种实验设备。
<艾美捷科技代理Stereospecific Detection Technologies品牌全系列产品
Stereospecific Detection Technologies (SDT)是一家专注于免疫分析、核酸杂交和免疫组织化学领域高性能试剂开发与生产的公司。Stereospecific Detection Technologies (SDT)生产用于ELISA、印迹(Blotting)、DNA/RNA杂交和IHC应用中超灵敏检测的试剂,Stereospecific Detection Technologies (SDT)提供三大类特种产品,以及各种免疫分析支持(辅助)试剂:多聚HRP和多聚GOD偶联物;多聚HRP稀释液、封闭剂和稳定剂;TMB 底物以及免疫分析辅助试剂。

▎Stereospecific Detection Technologies产品线
● Poly-HRP:Poly-HRP偶联物是Stereospecific Detection Technologies (SDT)独家生产的、用于超灵敏检测的独特产品。Stereospecific Detection Technologies (SDT)生产通用的:链霉亲和素-Poly-HRP、重组蛋白A-Poly-HRP、重组蛋白A/G-Poly-HRP偶联物,山羊抗小鼠IgG-Poly-HRP、兔抗小鼠IgG-Poly-HRP、山羊抗兔IgG-Poly-HRP、小鼠单克隆抗人IgG(H链, γ链特异性)-Poly-HRP和抗人 IgM (H链, µ链特异性)-Poly-HRP偶联物。
● PolyGOD:广泛应用在电化学免疫传感器、葡萄糖和氧传感、单层和多层薄膜免疫检测、过氧化物隧道免疫检测系统以及免疫组织化学(IHC)应用等领域。
● 专用辅助试剂:Stereospecific Detection Technologies (SDT)开发了用于制造高度浓缩、稳定且可通过0.2/0.45 µm滤膜过滤的酪蛋白胶体缓冲液,无生物素稀释液/封闭剂等特色产品。
● TMB底物及检测支持试剂:TMB底物包括超灵敏液态TMB(s(HS)TMB)、沉淀型膜用 TMB(p(HS)TMB)。检测支持试剂包括:浓缩的10% BSA溶液;HAMA 封闭剂;通用封闭剂;异嗜性抗体封闭剂。
▎Stereospecific Detection Technologies部分产品列表
| 品名 | 货号 | 规格 |
| Streptavidin-PolyHRP20 | #SP20C | 0.5 mg;1 mg;10 mg;25 mg |
| Streptavidin-PolyHRP40 | #SP40C | 0.5 mg;1 mg;10 mg;25 mg |
| Streptavidin-PolyHRP80 | #SP80C | 0.5 mg;1 mg;10 mg;25 mg |
| Mouse monoclonal anti-human IgG (H, γ-chain specific) DY649 labeled | #MAHG-DY649 | 0.5 mg;1 mg |
| Mouse monoclonal anti-human IgG (H, γ-chain specific) PolyHRP40 | #MAHGP-DY549C | 0.5 mg;1 mg |
| Giant Premium PolyStreptAvidin | #GPPSA | 1 mg;10 mg;25 mg;50 mg |
| Streptavidin-HRP, monomeric, cryopreserved | #SM1C | 1 mg;10 mg;25 mg |
| High Load StrongZyme™ Streptavidin-(Poly)HRP | #HL-SZ-SA | 1 mg;10 mg;25 mg |
| AmpliShine™ SA-PolyPE High Sensitivity Conjugate | #SAPE-AS | 1 mg |
| SA-(mono)PE IHC Grade Conjugate | #SAPE-M | 1 mg |
| recombinant Protein A - PolyHRP20 | #AP20C | 0.5 mg;1 mg;10 mg;25 mg |
| recombinant Protein A/G PolyHRP40 | #AGP40C | 0.5 mg;1 mg;10 mg |
| enhanced recombinant Protein A/G-PolyHRP40 | #AGP40C-WB | 0.5 mg;1 mg;10 mg |
| Goat anti-Mouse IgG (H+L)-PolyHRP40 | #GAMP40C | 0.5 mg;1 mg;10 mg;25 mg |
| Enhanced Streptavidin-PolyHRP Conjugate Stabilizer HTS-E | #SA1-HTS-E | 50 ml;100 ml;250 ml;500 ml;1000 ml;10 L |
| Streptavidin-PolyHRP Conjugate Stabilizer RHT(Real-Time High Temperature)synthetic | #SA3-RHT | 50 ml;100 ml;250 ml;500 ml;1000 ml;10 L |
| Antibody/Antigen (PolyHRP) Conjugate Stabilizer | #AA1 | 50 ml;100 ml;250 ml;500 ml;1000 ml;10 L |
| ep(HS)TMB-mA, enhanced stable precipitating 1-component TMB | #epTMB-mA | 30 ml;60 ml;125 ml;250 ml;500 ml;1000 ml |
| Stop/Elution Reagent for stopping | #SER | 65 ml;100 ml;250 ml;500 ml;1000 ml |
| Blocker of Human Anti-Mouse IgG Antibodies (HAMA) | #HAMAB | 10mg;100mg |
| 10% BSA, Ultra-pure, biotin and IgG free | #BSA1 | 10 ml;50 ml;100 ml;250 ml;500 ml;1000 ml |
| 10% BSA, trace biotin and IgG | #BSA2 | 10 ml;50 ml;100 ml;250 ml;500 ml;1000 ml |
| Binding/Coating Buffer 10X Concentrate | #BBC | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| Phosphate Buffered Saline (PBS) 10X Concentrate | #PBSC | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| Wash Buffer 20X Concentrate | #WBC-x20 | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| Substrate Buffer 10X Concentrate | #SBC | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| 5-Bromo-5-Nitro-1,3-Dioxane | #BND-D | 5 g;10 g;20 g;50 g;100 g;1000 g |

艾美捷科技代理Mediomics品牌。
Mediomics提供学术研究实验室、即时检测、制药公司以及医疗和环境研究市场所需的创新检测试剂盒和生物传感器。这些快速简单的检测试剂盒将用于定量许多具有生物学和治疗意义的大分子,包括:DNA、生物标志物、激素、抗体、细胞内信号分子、蛋白质-蛋白质复合物、细菌、真菌和病毒。Mediomics 的平台技术已经适用于检测一系列重要的大分子,包括 cAMP、色氨酸、S-腺苷甲硫氨酸、PDE、生物素、胰岛素、C 肽、白蛋白、C 反应蛋白 (hCRP)、IgG、IgM、大肠杆菌等。Mediomics的平台技术将能够生成全新的生物材料,可用于检测开发和治疗产品的开发。
Mediomics 目前拥有四项核心专有技术:
(1)Bridge-It®,灵敏、快速混合和测量 DNA 结合蛋白检测平台;
(2)PINCER,®快速混合和测量生物传感器、生物测定和生物芯片平台;
(3)创新的专有方法,用于筛选和开发用于研究、诊断和治疗的新型高亲和力捕获试剂;
(4)抗血管生成相关疗法。
" data-original="http://hooke.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Mediomics品牌"> 艾美捷科技代理Mediomics品牌
<艾美捷科技代理RA Biosources品牌全系列产品
RA Biosources,Inc.是由郭博士于2003年1月在美国加利福尼亚州贝尔蒙特创立的一家生物技术公司,专注于开发作为体外诊断试剂的单克隆抗体。经过多年的发展,RA Biosources公司产品线包括癌症标志物、滥用药物、传染源、胶原蛋白和细胞外基质蛋白、激素以及血清蛋白等。这显示了公司在生物技术研发方面的深厚实力和广泛覆盖。

▍RA Biosources部分产品列表
| 货号 | 同种型 | 品名 | 产品描述 |
| MA011 | IgG1 | Monoclonal Anti-human Alpha Fetoprotein (AFP) | This antibody reacts with AFP. There is no cross reactivity with human albumin, CEA, ferritin, hCG and PSA |
| MB034 | IgG1 | B2 Microglobulin | This antibody is specific to human beta-2 microglobulin |
| MC091 | IgG1 | Monoclonal Anti-CA12-5 | This antibody reacts with CA12-5 |
| MC123 | IgG1 | Monoclonal Anti-CA72-4 | This antibody reacts with CA72-4 |
| MC021 | IgG1 | Monoclonal Anti-human Carcinoembryonic Antigen (CEA) | This antibody reacts with CEA. There is no cross reactivity with human NCA, hCG and PSA |
| MF016 | IgG1 | Monoclonal Anti-human Ferritin | This antibody reacts with human ferritin |
| MG021 | IgG1 | Monoclonal Anti-human Growth Hormone (HGH) | This antibody reacts with human growth hormone |
| MP081 | IgG1 | Monoclonal Anti-Prostate Acid Phosphatase (PAP) | Specific to PAP |
| MP015 | IgG1 | Monoclonal Anti-human Prostate Specific Antigen (PSA) | This antibody reacts with free PSA and PSA-ACT (PSA-alpha 1-antichymotrypsin) complex. There is no cross reactivity with human kallikrein and ACT |
| MP016 | IgG1 | Monoclonal Anti-human PSA-ACT | This antibody reacts with PSA-ACT. There is no cross reactivity with free PSA and ACT |
| MP014 | IgG1 | Monoclonal Anti-human Free Prostate Specific Antigen (fPSA) | This antibody reacts only with free PSA. There is no cross reactivity with PSA-ACT, human kallikrein, or ACT |
| MC035 | IgG2a | Monoclonal Anti-Human Collagen Type IV | This antibody is specific to human collagen type IV |
| ML021 | IgG1 | human laminin | This antibody is specific to human laminin. It does not react with mouse laminin. |
| MF023 | IgG1 | Monoclonal Anti-Human Fibronectin | This antibody is specific to human fibronectin |
| ML031 | IgG1 | Monoclonal Anti-Mouse Laminin | This antibody is specific to mouse laminin. It does not react with human laminin. |
| MM102 | IgG1 | Monoclonal 6-Monoacetylmorphine (6MAM) | Mab to 6MAM |
| MA041 | IgG1 | Monoclonal AB-Pinaca | Mab to AB-Pinaca |
| MA022 | IgG2b | Monoclonal Anti-Amphetamine | Mab to amphetamine |
| MB011 | IgG1 | Monoclonal Anti-Barbiturates | Mab to barbiturates |
| MB021 | IgG1 | Monoclonal Anti-Benzoylecgonine | This antibody reacts with benzoylecgonine |
| MC082 | IgG1 | Monoclonal Anti-Clonazepam | This antibody reacts with clonazepam and 7-clonazepam |
| MC011 | IgG1 | Monoclonal Anti-Cotinine | Specific to cotinine |
| ME012 | IgG1 | Monoclonal Anti-EDDP | This antibody reacts with EDDP |
| MF041 | IgG1 | Monoclonal Anti-Fentanyl | Mab to fentanyl |
| MK015 | IgG1 | Monoclonal Anti-K2 | Mab to K2 |
| MK021 | IgG2b | Monoclonal Anti-Ketamine | Mab to ketamine |
| ML041 | IgG1 | Monoclonal Anti-Lysergic acid diethylamide (LSD) | Mab to LSD |
| MM091 | IgG1 | Monoclonal Anti-Melatonin | Mab to Melatonin |
| MM011 | IgG1 | Monoclonal Anti-Methadone | This antibody reacts with methadone |
| MM031 | IgG1 | Monoclonal Anti-Methylenedioxymethamphetamine (MDMA) | Mab to MDMA |
| MM063 | IgG1 | Monoclonal Anti-Methamphetamine | Mab to methamphetamine |
| MM111 | IgG1 | Monoclonal Anti-Methaqualone | This antibody reacts with methaqualone |
| MM071 | IgG2a | Monoclonal Anti-Methcathinone | Mab to methcathinone |
| MM083 | IgG1 | Monoclonal Anti-Methotrexate | Mab to methotrexate |
| MM041 | IgG1 | Monoclonal Anti-Morphine | This antibody reacts with morphine |
| MO022 | IgG1 | Monoclonal Anti-Oxycodone | This antibody reacts with oxycodone |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:15172469628
邮箱:sales@amyjet.com
0.1334